About Nuclein
Nuclein is a Healthcare company based in Austin (United States) founded in 2017. Handheld PCR devices for infectious disease detection are developed. Nuclein has raised $30.09 million across 7 funding rounds from investors including Trinity Investors. Nuclein offers products and services including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Screening. Its legal entity is Nuclein, LLC. Its competitors include CellScope, Orphidia and Mel-Mont Medical; 2 of its 3 listed competitors have raised funding.
Company details
Nuclein was founded in 2017 in Austin, United States, and operates in the medical diagnostics sector. A handheld PCR device named NUCLEIN is developed, utilizing standard real-time PCR technology. No technical expertise is required for operation, and the battery-powered unit delivers results within one hour. Applications include diagnosis of COVID-19 and other infectious diseases in field settings.
- Headquarters Austin, United States
- SectorsHealthcare
- Website nuclein.com
- Social LinkedIn X Facebook Instagram
- Legal Name Nuclein, Llc
- Total Equity Funding$30.09M (USD)
in 7 rounds
- Latest Funding Round$11.11M (USD), Series B
Jul 2026
- Investors
Products & Services of Nuclein
Nuclein offers a comprehensive portfolio of products and services, including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test.
Delivers lab-quality PCR results in 15 minutes for point-of-care use.
Enables detection of SARS-CoV-2 and influenza viruses via PCR.
Funding Insights of Nuclein
Nuclein has successfully raised a total of $30.09M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $11.11 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.09M
- Total Rounds 7
- Last Round Series B — $11.11M
- First Round $14M
(Mar 2021)
- Investors Count 1
All 7 funding rounds of Nuclein with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $11.11M | Series B | – | – | – |
| Jun 2026 | $1.3M | Debt – Conventional | – | – | – |
| Jul 2025 | $9.78M | Debt – Conventional | – | – | – |
| Jan 2025 | $750,000 | Series B | – | – | – |
| Dec 2023 | $8.79M | Debt – Conventional | – | – | – |
| Mar 2023 | $4.22M | Series B | – | – | – |
| Mar 2021 | $14M | Series B | – | Trinity Investors | – |
1 investors in total: 1 institutional.
Investors in Nuclein
Nuclein has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Trinity Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| trinityinvestors.com |
Investor details for Nuclein
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nuclein
13 people are tracked at Nuclein (8 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Mark Hunter | Vice President, Operations | Leadership |
Jeffrey Stukuls | CFO | Leadership |
Alan Blake | Chief Executive Officer | Leadership |
Huiping Zhu | Vice President, Assay Development | Leadership |
Michael Karberg | Chief Scientist | Leadership |
Brian Estes, GPHR, PHR | Chief People Officer | Leadership |
Reid Sadler | Chief Commercial Officer (cco) | Leadership |
Miranda Chavez | Director Of Program Management | Leadership |
Skyler Cadenhead | Product Development Manager | Team |
Jeannie Phipps | Controller | Team |
Ryan Cho | Senior Software Quality Engineer | Team |
Grant Kuempel | Senior Systems Integration Engineer | Team |
Johnathan Kwong, CQE, CQA | Quality Systems Manager | Team |
Complete people profiles for Nuclein
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nuclein
3 dated milestones of Nuclein across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Nuclein is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series B, of $11.1M.
Competitors of Nuclein
Nuclein has 3 listed competitors in our database, 2 of them funded. They include CellScope, Orphidia and Mel-Mont Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellscope.com | 2010 | San Francisco, United States | $4.62M | In-ear visibility is enabled by smartphone-attached otoscope for at-home diagnosis. | ||
| orphidia.com | 2013 | San Francisco, United States | Handheld device for point-of-care chronic disease diagnostics is developed. | |||
| mel-montmedical.com | 2014 | Doral, United States | $3M | Molecular screening devices for early infectious disease detection are developed. |
Detailed competitors of Nuclein
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nuclein
The website of Nuclein (nuclein.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 39.7% vs previous month
Top companies in Infectious Diseases
3 companies that operate in the same segment as Nuclein (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuclein
Complete news archive for Nuclein
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuclein
Nuclein was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Nuclein is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Nuclein is a funded company, having raised a total of $30.09M across 7 funding rounds to date. The company's 1st funding round was a Series B of $14M, raised on Mar 2021.
Nuclein was founded in 2017 in Austin, United States, and operates in the medical diagnostics sector. A handheld PCR device named NUCLEIN is developed, utilizing standard real-time PCR technology. No technical expertise is required for operation, and the battery-powered unit delivers results within one hour. Applications include diagnosis of COVID-19 and other infectious diseases in field settings.
Nuclein's top competitors include CellScope, Mel-Mont Medical and Orphidia.
Nuclein offers DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test.
Nuclein has 1 investor. Key investors include Trinity Investors.
Nuclein operates through Nuclein, Llc.